Cargando…

The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review

BACKGROUND: Natural resources provide more efficient and safer alternatives in managing diabetes compare to the synthetic oral anti diabetes (OAD). The plants not only have hypoglycemic effect, but also prevent its complications; in which no synthetic drugs provide of both properties. Among antidiab...

Descripción completa

Detalles Bibliográficos
Autores principales: Sukardiman, Ervina, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068623/
https://www.ncbi.nlm.nih.gov/pubmed/32190758
http://dx.doi.org/10.1016/j.heliyon.2020.e03536
_version_ 1783505622512173056
author Sukardiman
Ervina, Martha
author_facet Sukardiman
Ervina, Martha
author_sort Sukardiman
collection PubMed
description BACKGROUND: Natural resources provide more efficient and safer alternatives in managing diabetes compare to the synthetic oral anti diabetes (OAD). The plants not only have hypoglycemic effect, but also prevent its complications; in which no synthetic drugs provide of both properties. Among antidiabetes plants, mahogany seed (Swietenia macrophylla) has been used as traditional medicine in Indonesia and India, though most popular utilized as timber wood. METHODS: The present study was performed of chemotaxonomic approach to review its phytochemical and anti-diabetic properties of Swietenia mahagoni (L.) Jacq seed/bark/leaves. The qualitative systematic review (SR) was carried out by analysing indexed journals and peer reviewed of Swietenia and Swietenia spp from Scopus, PubMed, Medline, Google Scholar, and Research Gate. Data selection criteria are accordance to botany, phytochemistry, in vitro, in vivo, and clinical test of related subject. The keywords used for the search in the databases were Swietenia, Swietenia mahagony, diabetes, and diabetes plants. RESULTS: Swietenia mahagoni (L.) Jacq. extracts have shown in vitro, in vivo and limited clinically test of its anti-diabetic properties. Ethanolic/methanolic/aqueous/petroleum/n-hexane extracts of mahagonis's seed/bark or leaves have anti-diabetic activities comparable to the synthetic drug and observed no to relatively mild toxic effect. The hypoglycemic mechanism suggested via reducing blood glucose level, restoring liver and β-cells islet function (might) blocking epinephrine function, inhibiting of α-amylase and β-glucosidase, antioxidant and antihiperlipidemia. Phytochemical compounds of S. mahagoni consist of the phenolics (flavonoids (swietemacrophyllanin, catechins and epichatechins) and tannins), triterpenoids and tetranortriterpenoids (limonoids: mahonin, secomahoganin, swietmanins, swiemahogins, swietenine and swietenolide), saponins and alkaloids which are known as anti-diabetic bioactive principles. CONCLUSION: S. mahagoni was potentially used and developed as an antidiabetes source. To use it as an antidiabetic further, more extensive clinical trials and biomarkers of active compounds determination are needed.
format Online
Article
Text
id pubmed-7068623
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70686232020-03-18 The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review Sukardiman Ervina, Martha Heliyon Article BACKGROUND: Natural resources provide more efficient and safer alternatives in managing diabetes compare to the synthetic oral anti diabetes (OAD). The plants not only have hypoglycemic effect, but also prevent its complications; in which no synthetic drugs provide of both properties. Among antidiabetes plants, mahogany seed (Swietenia macrophylla) has been used as traditional medicine in Indonesia and India, though most popular utilized as timber wood. METHODS: The present study was performed of chemotaxonomic approach to review its phytochemical and anti-diabetic properties of Swietenia mahagoni (L.) Jacq seed/bark/leaves. The qualitative systematic review (SR) was carried out by analysing indexed journals and peer reviewed of Swietenia and Swietenia spp from Scopus, PubMed, Medline, Google Scholar, and Research Gate. Data selection criteria are accordance to botany, phytochemistry, in vitro, in vivo, and clinical test of related subject. The keywords used for the search in the databases were Swietenia, Swietenia mahagony, diabetes, and diabetes plants. RESULTS: Swietenia mahagoni (L.) Jacq. extracts have shown in vitro, in vivo and limited clinically test of its anti-diabetic properties. Ethanolic/methanolic/aqueous/petroleum/n-hexane extracts of mahagonis's seed/bark or leaves have anti-diabetic activities comparable to the synthetic drug and observed no to relatively mild toxic effect. The hypoglycemic mechanism suggested via reducing blood glucose level, restoring liver and β-cells islet function (might) blocking epinephrine function, inhibiting of α-amylase and β-glucosidase, antioxidant and antihiperlipidemia. Phytochemical compounds of S. mahagoni consist of the phenolics (flavonoids (swietemacrophyllanin, catechins and epichatechins) and tannins), triterpenoids and tetranortriterpenoids (limonoids: mahonin, secomahoganin, swietmanins, swiemahogins, swietenine and swietenolide), saponins and alkaloids which are known as anti-diabetic bioactive principles. CONCLUSION: S. mahagoni was potentially used and developed as an antidiabetes source. To use it as an antidiabetic further, more extensive clinical trials and biomarkers of active compounds determination are needed. Elsevier 2020-03-10 /pmc/articles/PMC7068623/ /pubmed/32190758 http://dx.doi.org/10.1016/j.heliyon.2020.e03536 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sukardiman
Ervina, Martha
The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_full The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_fullStr The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_full_unstemmed The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_short The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review
title_sort recent use of swietenia mahagoni (l.) jacq. as antidiabetes type 2 phytomedicine: a systematic review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068623/
https://www.ncbi.nlm.nih.gov/pubmed/32190758
http://dx.doi.org/10.1016/j.heliyon.2020.e03536
work_keys_str_mv AT sukardiman therecentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview
AT ervinamartha therecentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview
AT sukardiman recentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview
AT ervinamartha recentuseofswieteniamahagoniljacqasantidiabetestype2phytomedicineasystematicreview